TrialJournal of managed care & specialty pharmacy2022

Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.

Jingjing Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.